
Biogen Idec and Isis Pharmaceuticals have entered their fourth partnership in two years in a deal that will see the …

Rival MS treatments from Biogen Idec and Genzyme have both received European approval. The CHMP has recommended marketing authorisation for …

Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …
Biogen Idec has a new head of research and development, appointing Douglas Williams to oversee its global operations. The position …
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

